FDA Credibility Crisis: 1990 Generic Drug Scandal May Be Blueprint For 2005
Executive Summary
FDA is heading into 2005 facing the most difficult challenge to its credibility as a regulatory agency since the generic drug scandal at the end of the 1980s
You may also be interested in...
Generic Biologics Warning From FDA: Implementation Resources Needed
With the expectation that language to establish a generic biologics approval pathway will be included in the FDA Revitalization Act, former FDA commissioner Frank Young warned of the need for adequate resources
Generic Biologics Warning From FDA: Implementation Resources Needed
With the expectation that language to establish a generic biologics approval pathway will be included in the FDA Revitalization Act, former FDA commissioner Frank Young warned of the need for adequate resources
Tarceva, Kepivance, And Macugen Approvals Are Quiet Milestones For FDA
Genentech/OSI's Tarceva, Amgen's Kepivance and Pfizer/Eyetech's Macugen are the first three products approved under the "continuous marketing application" pilot program